Hanker, A. B., Estrada, M. V., Bianchini, G., Moore, P. D., Zhao, J., Cheng, F., … Arteaga, C. L. (2019). Correction: Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer. Cancer Res, 79(4), 873. https://doi.org/10.1158/0008-5472.CAN-18-4085

Hanker, Ariella B., Mónica Valeria Estrada, Giampaolo Bianchini, Preston D. Moore, Junfei Zhao, Feixiong Cheng, James P. Koch, et al. “Correction: Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer.” Cancer Res 79, no. 4 (February 15, 2019): 873. https://doi.org/10.1158/0008-5472.CAN-18-4085.

Hanker AB, Estrada MV, Bianchini G, Moore PD, Zhao J, Cheng F, et al. Correction: Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer. Cancer Res. 2019 Feb 15;79(4):873.

Hanker, Ariella B., et al. “Correction: Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer.” Cancer Res, vol. 79, no. 4, Feb. 2019, p. 873. Pubmed, doi:10.1158/0008-5472.CAN-18-4085.

Hanker AB, Estrada MV, Bianchini G, Moore PD, Zhao J, Cheng F, Koch JP, Gianni L, Tyson DR, Sánchez V, Rexer BN, Sanders ME, Zhao Z, Stricker TP, Arteaga CL. Correction: Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer. Cancer Res. 2019 Feb 15;79(4):873.